About
ProSciento provides scientific and operational expertise in the design and management of all facets of clinical development for NASH, diabetes, obesity, and related metabolic drug and device studies.
![Customized Programs for Clinical Development and Global Regulatory Services thumbnail](https://prosciento.com/wp-content/uploads/2021/12/thumbnail-6.png)
Recommended Materials
![Customized Programs for Clinical Development and Global Regulatory Services thumbnail](https://prosciento.com/wp-content/uploads/2022/01/journal-32.png)
Articles
Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide
![Customized Programs for Clinical Development and Global Regulatory Services thumbnail](https://prosciento.com/wp-content/uploads/2022/01/journal-36.png)
Articles
Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2
![Customized Programs for Clinical Development and Global Regulatory Services thumbnail](https://prosciento.com/wp-content/uploads/2022/01/journal-51.png)
Articles
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males
Related Solutions
![Overview thumbnail](https://prosciento.com/wp-content/uploads/2023/08/our-services-overview-thumbnail.jpg)
Our Services
![Metabolic Continuum thumbnail](https://prosciento.com/wp-content/uploads/2023/08/our-metabolic-focus-overview-thumbnail.jpg)